Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Archive ouverte

Fraison, Jean-Baptiste | Mekinian, Arsène | Grignano, Eric | Kahn, Jean-Emmanuel | Arlet, Jean-Benoit | Decaux, Olivier | Denis, Guillaume | Buchdahl, Anne-Laure | Omouri, Mohamed | Maigne, Gwenola | Aouba, Achille | Leon, Nathalie | Berthier, Sabine | Liozon, Eric | Park, Sophie | Gardin, Claude | Lortholary, Olivier | Rossignol, Julien | Fenaux, Pierre | Fain, Olivier | Braun, Thorsten

Edité par CCSD ; Elsevier -

International audience. This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion